Multipotent mesenchymal stromal cells express FoxP3: A marker for the immunosuppressive capacity?

Journal of Immunotherapy

Volumn 34, Issue 4, 2011, Pages 336-342

  Sundin, Mikael ^a   D'Arcy, Pádraig ^b   Johansson, C Christian ^b   Barrett, A John ^c   Lönnies, Helena ^d   Sundberg, Berit ^d   Nava, Silvia ^d   Kiessling, Rolf ^b   Mougiakakos, Dimitrios ^b   Le Blanc, Katarina ^a,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Cancer Centre Karolinska   (Sweden)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

forkhead box 3; mesenchymal stem cells; transplantation

Indexed keywords

AZACITIDINE; CD39 ANTIGEN; MARKER; METHYLPREDNISOLONE; RAPAMYCIN; SMALL INTERFERING RNA; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CELL TYPE; CHILD; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE CULTURE; MESENCHYME CELL; MULTIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; INFANT; LYMPHOCYTES; MESENCHYMAL STEM CELLS; MULTIPOTENT STEM CELLS; STROMAL CELLS; YOUNG ADULT;

EID: 79955583551     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318217007c     Document Type: Article

References (42)

1. Shevach EM, DiPaolo RA, Andersson J, et al. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev. 2006;212:60-73. (Pubitemid 44116700)
2. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190:995-1004.
3. Belkaid Y, Piccirillo CA, Mendez S, et al. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420:502-507. (Pubitemid 35477041)
4. Fahlen L, Read S, Gorelik L, et al. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2005;201:737-746. (Pubitemid 40395119)
5. Kullberg MC, Hay V, Cheever AW, et al. TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation. Eur J Immunol. 2005;35:2886-2895. (Pubitemid 41555084)
6. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101:3722-3729. (Pubitemid 36857965)
7. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105:2214-2219. (Pubitemid 40731815)
8. Rasmusson I, Ringden O, Sundberg B, et al. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res. 2005;305:33-41. (Pubitemid 40380651)
9. Ryan JM, Barry FP, Murphy JM, et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;2:8.
10. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262: 509-525. (Pubitemid 47620502)
11. Sundin M, Barrett AJ, Ringden O, et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother. 2009;32:755-764.
12. Sundin M, Ringden O, Sundberg B, et al. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica. 2007;92: 1208-1215. (Pubitemid 350144179)
13. Togel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol. 2005;289:F31-F42. (Pubitemid 40863570)
14. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA. 2003;100:8407-8411. (Pubitemid 36842558)
15. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106:1755-1761. (Pubitemid 41208591)
16. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363: 1439-1441. (Pubitemid 38586721)
17. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390-1397. (Pubitemid 43847148)
18. Muller I, Kordowich S, Holzwarth C, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis. 2008;40:25-32. (Pubitemid 350199635)
19. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061. (Pubitemid 36222930)
20. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330-336. (Pubitemid 36432314)
21. Khattri R, Cox T, Yasayko SA, et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4:337-342. (Pubitemid 36432315)
22. Li B, Saouaf SJ, Samanta A, et al. Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression. Curr Opin Immunol. 2007;19:583-588. (Pubitemid 47487453)
23. Li B, Samanta A, Song X, et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA. 2007;104: 4571-4576. (Pubitemid 47186266)
24. Salcido-Ochoa F, Tsang J, Tam P, et al. Regulatory T cells in transplantation: does extracellular adenosine triphosphate metabolism through CD39 play a crucial role? Transplant Rev (Orlando). 2010;24:52-66.
25. Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007;21:1733-1738. (Pubitemid 47086763)
26. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317. (Pubitemid 44269669)
27. Le Blanc K, Rasmusson I, Gotherstrom C, et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol. 2004;60:307-315. (Pubitemid 39141263)
28. Moller G. Induction of DNA synthesis in human lymphocytes: interaction between non-specific mitogens and antigens. Immunology. 1970;19:583-598.
29. Mougiakakos D, Johansson CC, Kiessling R. Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood. 2009;113:3542-3545.
30. Bohler T, Nolting J, Kamar N, et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit. 2007;29:77-86. (Pubitemid 46279880)
31. Jones DL, Sacks SH, Wong W. Controlling the generation and function of human CD8+ memory T cells in vitro with immunosuppressants. Transplantation. 2006;82:1352-1361. (Pubitemid 44832918)
32. Puzik A, Schultz C, Iblher P, et al. Effects of ciclosporin A, tacrolimus and sirolimus on cytokine production in neonatal immune cells. Acta Paediatr. 2007;96:1483-1489. (Pubitemid 47416444)
33. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graftversus- host disease: a phase II study. Lancet. 2008;371: 1579-1586. (Pubitemid 351626841)
34. Vela-Ojeda J, Montiel-Cervantes L, Granados-Lara P, et al. Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation. Stem Cells Dev. 2010;19: 330-340.
35. Sagoo P, Lombardi G, Lechler RI. Regulatory T cells as therapeutic cells. Curr Opin Organ Transplant. 2008;13:645-653.
36. Nguyen VH, Zeiser R, Negrin RS. Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12:995-1009.
37. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110: 1225-1232. (Pubitemid 47281420)
38. Kobie JJ, Shah PR, Yang L, et al. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 50-adenosine monophosphate to adenosine. J Immunol. 2006;177: 6780-6786. (Pubitemid 44715042)
39. Schubert LA, Jeffery E, Zhang Y, et al. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem. 2001;276:37672-37679.
40. Lipscomb MW, Taylor JL, Goldbach CJ, et al. DC expressing transgene Foxp3 are regulatory APC. Eur J Immunol. 2010; 40:480-493.
41. Racila R, Melchinger W, Finke J, et al. Everolimus enhances the Immunomodulatory Properties of CD271 Positive Selected Human Mesenchymal Stem Cells. 34th Annual Meeting of the European Group for Blood and Marrow Transplantation. Florence, Italy: Bone Marrow Transplantation; 2008.
42. Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood. 2009;114:3727-3735.